Enteris BioPharma Announces Acceptance
of Two Abstracts for Presentation
at ENDO 2022 Annual Conference
Boonton, NJ – April 12, 2022 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today that two submitted abstracts were accepted for poster presentations at the 104th annual meeting of The Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta, Georgia. The abstracts highlight research into oral formulations of leuprolide developed utilizing Enteris' proprietary Peptelligence® platform, a novel formulation technology that enables oral delivery of molecules that are typically injected, including peptides and BCS class III and IV small molecules.
READ FULL PRESS RELEASE
Meet Enteris Biopharma at ENDO 2022
June 11-14, Atlanta, GA
To learn more about our technologies and CMO service offerings please fill out and submit the form.